NEW YORK and LONDON, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today the appointment of Robert Ward to its Board of Directors. Mr. Ward brings over twenty-five years of pharmaceutical experience to
The 2nd annual aHUS Awareness Day will be marked on 24 September 2016. Updates from aHUS patient organizations and supporters from around the world will be visible on Twitter at @aHUSallianceAct and @aHUS24Sept. 2016 aHUS Awareness Day resources, news, and information will added throughout
NEW YORK and LONDON, Sept. 18, 2015 (GLOBE NEWSWIRE) -- Celsus Therapeutics Plc (NASDAQ: CLTX ) and Volution Immuno Pharmaceuticals SA today announced that, following shareholder approval obtained at a general meeting of the shareholders of Celsus held on September 16, 2015, the previously
NEW YORK and LONDON, Sept. 16, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced that Dr. Gur Roshwalb, Chief Executive Officer, will present at two upcoming investor conferences: Ladenburg Thalmann 2016 Healthcare
NEW YORK and LONDON, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, development-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted to Akari an Orphan Drug Designation for recombinant protein
NEW YORK and LONDON, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that Dr. Gur Roshwalb, Chief Executive Officer, will present at the 36th Annual Canaccord|Genuity Growth Conference on August 10
NEW YORK and LONDON, July 13, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today the approval by the UK Medicines & Healthcare products Regulatory Agency (MHRA) to conduct a Phase 2 trial in patients with
NEW YORK and LONDON, July 12, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, announced today that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending
NEW YORK and LONDON, July 06, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, today announced positive interim data from the first cohort in its Phase Ib trial which demonstrates maintenance of complement inhibition using
NEW YORK and LONDON, June 15, 2016 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX ), an emerging growth, clinical-stage biopharmaceutical company, today announced that Dr. Gur Roshwalb, Chief Executive Officer, will participate in a fireside chat and provide an overview of the company at the
